Eff ectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021

Eff ectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021

By: Glatman-Freedman A., Hershkovitz Y., Kaufman Z., Dichtiar R., Keinan-Boker L., Bromberg M.
Published in: Emerging Infectious Diseases
SDGs : SDG 03  |  Units: Social Welfare & Health Sciences  | Time: 2021 |  Link
Description: In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolesce nts in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine eff ectiveness and found the vaccine to be highly eff ective among this population in this setting. © 2021 Centers for Disease Control and Prevention (CDC). All rights reserved.